The company intends to use the funds for the clinical advancement of its lead product candidate Obexelimab, including a global Phase 3 registration trial in patients with IgG4-related disease (IgG4-RD), which will be initiated in late 2022. In addition, the new funding will progress other global autoimmune disease programs into clinical development in 2023.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1000 Winter St North Building 1200
Waltham, MA 02451
USA

Phone

Undisclosed

Website

www.zenasbio.com

Email Address

[email protected]

Overview

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology based therapies for patients in need. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Hua Mu

Chief Operating Officer

Joe Farmer

Founder

Lonnie Moulder

Browse more venture capital transactions:

Prev: 11/8/2022: Archax venture capital transaction
Next: 11/8/2022: Teamraderie venture capital transaction

Share this article

About Our VC Transactions Data

We record every notable VC transaction. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary